Serum leptin and IGF-I during growth hormone treatment in chronic renal failure

Leena Patel, Nicholas J A Webb, Mark G. Bradbury, Nasra Zaman, Patricia Smith, Malcolm A. Lewis, Robert J. Postlethwaite, David A. Price, Peter E. Clayton

    Research output: Contribution to journalArticlepeer-review


    Serum leptin decreases during growth hormone (hGH) treatment and pre-treatment values have been suggested as a predictor of the response to hGH in GH deficiency (GHD) but not in non-GHD syndromes. To investigate whether this holds true in children with chronic renal failure (CRF), we evaluated changes in serum leptin, insulin-like growth factor-I (IGF-I) and height beforeb and during the 1st year (3 months, 6 months, 9 months, 12 months) of hGH treatment (1 IU/kg per week) in 11 children (median ageb 10.1 years, mean heightb -2.9 SDS) with CRF. Serum leptin and IGF-I were compared with values from healthy children. Each patient also served as his/her own control, with values during treatment compared with those before treatment. Growth improved in all patients during treatment (mean change12m +7.2 cm, change in height SDS12m +0.5, P=0.001). Weight decreased (median decrease12m 0.3 SDS, P=0.02) but body mass index (BMI) and serum leptin did not change during treatment. Serum IGF-I levels were low before (mean -1.1 SDS) but increased during hGH treatment, the increment being greatest at 10 days (mean increment +1.9 SDS, P
    Original languageEnglish
    Pages (from-to)643-647
    Number of pages4
    JournalPediatric Nephrology
    Issue number8
    Publication statusPublished - 2002


    • Chronic renal failure
    • Growth hormone treatment
    • Insulin-like growth factor-I
    • Leptin


    Dive into the research topics of 'Serum leptin and IGF-I during growth hormone treatment in chronic renal failure'. Together they form a unique fingerprint.

    Cite this